Xenoport, Inc.
Get Full AccessDescription
- XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.
-
Headquarters: , , , United States
More -
Phone Number:
-
Website: https://www.xenoport.com
-
Employees:132
-
Revenue:$10 - 50M
-
Legal Name:Xenoport, Inc.
-
Xenoport, Inc.'s Social Media
-
Is this data correct?
-
| NAICS Code: 325412 |
Show More
Sell more in less time!
Buyer intent data, anonymous visitor identification, first party data integration backed by a massive contact database that will supercharge your sales team. Schedule a demo to learn more!
Frequently Asked Questions regarding Xenoport, Inc.
-
What is Xenoport, Inc.'s official website?
Xenoport, Inc.'s official website is https://www.xenoport.com
-
What is Xenoport, Inc.'s Revenue?
Xenoport, Inc.'s revenue is $10 - 50M
-
What is Xenoport, Inc.'s NAICS code?
Xenoport, Inc.'s NAICS code is 325412
-
How many employees are working in Xenoport, Inc.
Xenoport, Inc. has 132 employees
-
What is Xenoport, Inc.'s Industry?
Xenoport, Inc. is in the industry of Pharmaceuticals
-
Who is Xenoport, Inc.'s Vice President, Chief Patent Counsel?
Xenoport, Inc.'s Vice President, Chief Patent Counsel is Byron Miller
-
Who is Xenoport, Inc.'s Vice President, Market Access?
Xenoport, Inc.'s Vice President, Market Access is Bill Soucie
-
Who is Xenoport, Inc.'s Director?
Xenoport, Inc.'s Director is Thamil Annamalai